Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board

Pioneer of Tumor Immunotherapy Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board

Former President of the Society for Immunotherapy of Cancer to Assist Company in Advancement of its Anti-Angiogenesis Immunotherapy Product ValloVax

Batu Biologics, committed to advancement of its clinical stage cancer immunotherapeutic, ValloVax™, announced today the appointment of Dr. Francesco Marincola as the Chairman of the Company’s Clinical Advisory Board.

Read the full article at businesswire.com

Batu Biologics CEO to Moderate Congressional Immunotherapy Symposium

Batu Biologics Chief Executive Officer Samuel Wagner to Moderate Congressional Immunotherapy Symposium

Congressional Candidate to Hear Concerns of Industry Leaders in Health Care Innovations

Batu Biologics, a clinical stage immunotherapy company, announced today its Chief Executive Officer, Samuel Wagner, was chosen to moderate an internationally renowned panel of biotechnology companies focusing on immunotherapy.

Read the full article at businesswire.com

Batu Biologics CEO Selected for Lyfebulb Oncology Award

Batu Biologics CEO Selected as Finalist for Lyfebulb-Helsinn Innovation Summit and Award For Oncology

Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, today announced the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology.

Read the full article at globalnewswire.com

Batu Biologics Receives FDA IND Clearance

Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer

Company’s First-in-Class Drug, ValloVax, Acts by Educating Immune System to Starve Tumors

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) allowing Batu to proceed with Phase 1 clinical trials.

Read the full article at businesswire.com

Batu Chooses Unusual Path, Unusual Weapon

Crowdfunding Part of Financial Strategy; Cancer Fight Aims to Cut Tumors’ Blood Supply

When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… the company has filed 29 patents, raised over $2 million, and is gearing up to start testing its anti-cancer vaccine in humans.

Download full article here

Batu Biologics Launches #starvethetumor Campaign

Batu Biologics Launches #starvethetumor Crowdfunding Campaign for ValloVax Cancer Immunotherapy

Company is hosting a press conference on May 11th, 2017 to discuss our strategy for ValloVax development

Batu Biologics, an immuno-oncology company dedicated to studying blood vessel formation within tumors, announced today the launch of an equity crowdfunding campaign on EquityNet.

Read the full article at businesswire.com

Batu Publishes Oncotarget Paper

Batu Biologics Publishes Mechanistic Preclinical Data for ValloVax

Company authors peer reviewed publication describing the mechanism of action of the ValloVax™ mediated immune response

Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget.

Read the full article at businesswire.com

Batu Biologics recruits San Diego Biotech Investor to BOD

Batu Biologics Welcomes Rancho Santa Fe Biotech Investor to Board of Directors

Batu Biologics Seed Round Investor John Peck Jr. to join Board of Directors

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of John Peck Jr., to its Board of Directors.

Read the full article at businesswire.com

Batu announces formation of Clinical Advisory Board

Batu Biologics Welcomes Three Visionary Leaders to Its Newly Formed Clinical Advisory Board

CAB to oversee the clinical development of Batu Biologics’ tumor vasculature targeting immunotherapeutic, ValloVax™

Batu Biologics, a San Diego based immuno-oncology company focused on the development of its tumor angiogenesis targeting immune therapy, ValloVax™, announced today the formation of a Clinical Advisory Board to guide the company in the development of its lead program.

Read the full article at businesswire.com